1. World Health Organization (WHO). Chronic obstructive pulmonary disease (COPD); 2022. Available from: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)#:~:text=Chronic%20obstructive%20pulmonary%20disease%20(COPD)%20is%20the%20third%20leading%20cause,%2Dincome%20countries%20(LMIC). Accessed May 2, 2022.
2. Global Initiative for Chronic Obstructive Lung Disease. 2021 Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2021. Available from: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf. Accessed April 1, 2021.
3. Real-World Treatment Patterns of Multiple-Inhaler Triple Therapy Among Patients with Chronic Obstructive Pulmonary Disease in UK General Practice
4. European Medicines Agency. Trelegy Ellipta EPAR summary of product characteristics; 2018. Available from: https://www.ema.europa.eu/en/documents/product-information/trelegy-Ellipta-epar-product-information_en.pdf. Accessed April 1, 2021.
5. Electronic Medicines Compendium. Trimbow 87 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution; 2017. Available from: https://www.medicines.org.uk/emc/medicine/33828#gref. Accessed April 1, 2021.